Physician profile
Raphael N Dodoo
NPI 1508835497
$3,856.12
in general payments reported to CMS, 2019-2025
26 companies · $555 in 2025
The $555 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $257 · 2021: $455 · 2022: $708 · 2023: $593 · 2024: $774 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.62 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $664.19 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $399.17 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $389.94 | 2021-2025 | |
| Glaxosmithkline, LLC. | $378.93 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.12 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $230.86 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $195.33 | 2021-2024 | Vraylar |
| Amgen INC. | $184.84 | 2019-2025 | Krystexxa, Tavneos |
| Pfizer INC. | $154.82 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $127.46 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.39 | 2019-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $82.26 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $80.35 | 2020-2021 | |
| Mylan Specialty L.P. | $75.76 | 2021-2024 | Yupelri |
| Abbott Laboratories | $71.28 | 2024-2025 | Freestyle Libre 3 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $62.44 | 2025 | Yupelri |
| Horizon Therapeutics Plc | $60.47 | 2021-2023 | Krystexxa |
| Allergan, INC. | $47.44 | 2020 | |
| Xeris Pharmaceuticals, INC. | $43.54 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $41.02 | 2022 | |
| Sanofi-Aventis U.S. LLC | $28.42 | 2019 | |
| Celgene Corporation | $28.19 | 2019 | |
| Lundbeck LLC | $27.24 | 2024 | Abilify Maintena |
| Novartis Pharmaceuticals Corporation | $22.15 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $20.41 | 2019 | |
| Exact Sciences Corporation | $18.10 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Dodoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.